Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical research trials and Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma. Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma clinical trial. Subjects typically recieve the finest healthcare available for their Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.

Home > "S" Clinical Trials Conditions > Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma



Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma

For Condition: Melanoma,Neoplasm Metastasis
Status: Completed
Sponsor(s): Celgene Corporation ,
Synopsis: Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Understand and voluntarily sign an informed consent form. - Able to adhere to the study visit schedule and other protocol requirements. - Metastatic malignant melanoma now stage IV, relapsed or refractory to standard metastatic therapy. - Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of starting study drug. - Patients with active brain disease, or newly diagnosed brain metastases, within 4 weeks prior to the start of study treatment are excluded.
Total Enrollment: 274

Location and Contact Information:

MD Anderson Cancer Center
Houston,  Texas,  77030-4009
United States
 

Spectrum Health
Grand Rapids,  Michigan,  49503
United States
 

Cancer Care Manitoba
Winnipeg,  Manitoba,  R3E 0V9
Canada
 

Cross Cancer Institute
Edmonton,  Alberta,  T6G 1Z2
Canada
 

Princess Margaret Hospital
Toronto,  Ontario,  M5G 2M9
Canada
 

Penn State Hershey Medical Center
Hershey,  Pennsylvania,  17033-0850
United States
 

Massachusetts General Hospital
Boston,  Massachusetts,  02214-2698
United States
 

Lutheran General
Park Ridge,  Illinois,  60068-1270
United States
 

Washington University School of Medicine
St. Louis,  Missouri,  63110
United States
 

Carle Clinic
Urbana,  Illinois,  61801
United States
 

University of Colorado
Aurora,  Colorado,  80010
United States
 

The Linder Clinical Trial Center
Cincinnati,  Ohio,  45219
United States
 

Biomedical Research Alliance of New York
New York City,  New York,  10016
United States
 

Beth Israel Deaconess Medical Ctr
Boston,  Massachusetts,  02215-5400
United States
 

Outpatient Clinic
Santa Monica,  California,  90404
United States
 

UPMC Cancer Pavillion
Pittsburgh,  Pennsylvania,  15232
United States
 

Sarah Cannon Cancer Center
Nashville,  Tennessee,  37203-1632
United States
 

Lakeland Regional Cancer Center
Lakeland,  Florida,  33804-1057
United States
 

Qell Health Sciences Center
Halifax,  Nova Scotia,  B3H 2y9
Canada
 

Cleveland Clinic Foundation
Cleveland,  Ohio,  44195
United States
 

University of Southern California Norris Cancer Center
Los Angeles,  California,  90089
United States
 

UCLA
Los Angeles,  California,  90095-6956
United States
 

Mount Sinai Comprehensive Cancer Center
Miami,  Florida,  33140
United States
 

Melanoma Center of St Louis
St. Louis,  Missouri,  63131
United States
 

Memorial Sloan Kettering Cancer Center
New York City,  New York,  10021
United States
 

The Harold Lever Regional Cancer Center
Waterbury,  Connecticut,  06708
United States
 

L'Hotel Dieu de Quebec
Quebec,  ,  PQ G1R 2J6
Canada
 

University of Arizona Cancer Center
Tucson,  Arizona,  85724
United States
 

Ellis Fischel Cancer Center
Columbia,  Missouri,  65203
United States
 

St. Francis Memorial Hospital
San Francisco,  California,  94109
United States
 

Tom Baker Cancer Center
Calgary,  Alberta,  T2N 4N2
Canada
 


Additional Information:
Study ID Numbers:
  CDC-5013-MEL-001; 
Study Start Date: January 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00055562

Other Neoplasm Metastasis Studies:
1. Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated with Dose-Intensive Chemotherapy

2. A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients with Metastatic Renal Cancer

3. A Multimodality Treatment Approach to Patients with Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer

4. Immunization of Patients with Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen

5. Immunization of Patients with Metastatic Melanoma Using MART-1 and GP100 Peptides Modified to Increase Binding to HLA-0201

Related Studies:

Other Neoplasm Metastasis Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects with Metastatic Malignant Melanoma

Modify your Search

  Other Neoplasm Metastasis Clinical Trials
  Other California Clinical Trials
  Other San Francisco Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103